Verona Pharma Stock (NASDAQ:VRNA), Quotes and News Summary

Q: What sector and industry does Verona Pharma (VRNA) operate in?

Verona Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Verona Pharma Stock (NASDAQ: VRNA) stock price, news, charts, stock research, profile.

Open	$16.020
Close	-
Volume / Avg.	134.848K / 443.324K
Day Range	15.450 - 16.200
52 Wk Range	11.830 - 23.810
Market Cap	$1.202B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	42
Short Interest	8.86%
Days to Cover	18.81

Recent News

Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion (£1.6 billion) range over the upcoming six months, aiming to fortify its pipeline.

Vandana Singh

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion. RayzeBio shares gained 100% to $61.38 on Tuesday.

Avi Kapoor

Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday

HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on Monday.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trend

Dec 23

Jan

Mar

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Verona Pharma Plc

Sector

Health Care

Industry

Pharmaceuticals

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercial...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Verona Pharma (VRNA) stock?

You can purchase shares of Verona Pharma (NASDAQ: VRNA) through any online brokerage.

View our list of the best stock brokerages.

Who are Verona Pharma's (VRNA) competitors?

Other companies in Verona Pharma’s space includes: Supernus Pharmaceuticals (NASDAQ:SUPN), Tarsus Pharmaceuticals (NASDAQ:TARS), ANI Pharmaceuticals (NASDAQ:ANIP), Neumora Therapeutics (NASDAQ:NMRA) and Longboard Pharmaceuticals (NASDAQ:LBPH).

What is the target price for Verona Pharma (VRNA) stock?

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by Piper Sandler on Tuesday, April 16, 2024. The analyst firm set a price target for 36.00 expecting VRNA to rise to within 12 months (a possible 123.60% upside). 15 analyst firms have reported ratings in the last year.

Current Stock Price for Verona Pharma (VRNA)?

The stock price for Verona Pharma (NASDAQ: VRNA) is $16.1 last updated April 18, 2024 at 4:00 PM EDT.

Does Verona Pharma (VRNA) pay a dividend?

There are no upcoming dividends for Verona Pharma.

When is Verona Pharma (NASDAQ:VRNA) reporting earnings?

Verona Pharma’s Q1 earnings are confirmed for Tuesday, May 7, 2024.

Is Verona Pharma (VRNA) going to split?

There is no upcoming split for Verona Pharma.

What sector and industry does Verona Pharma (VRNA) operate in?

Verona Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-